Galderma

NEWS DESK

Galderma Receives U.S. FDA Approval for Nemluvio

News Desk 1 15/12/2024 0

Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or

NEWS DESK

EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy

News Desk 1 26/09/2024

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and prurigo nodularis, respectively, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam during three separate oral presentations. These late-breaking data will be presented on

NEWS DESK

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

News Desk 1 17/09/2024

Galderma (SWX:GALD), the pure-play dermatology category leader, announced today it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024, reinforcing its commitment to advancing dermatology for every skin story. In

NEWS DESK

Galderma Successfully Issued an Inaugural CHF 500 Million Bond

News Desk 1 29/08/2024

Galderma successfully placed an inaugural bond with a total amount of CHF 500 million through a dual tranche offering: The payment date of the bonds is September 27, 2024. The bonds will be listed on the SIX Swiss Exchange and are expected to be included in the domestic segment of the Swiss Bond Index (SBI). […]

NEWS DESK

Galderma Receives U.S. FDA Approval for Nemluvio

News Desk 1 13/08/2024

Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis.1 Nemluvio was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. FDA – a status reserved for medicines with

NEWS DESK

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

News Desk 1 05/08/2024

Galderma today announced that it has signed a memorandum of understanding with L’Oréal to work towards a new research and development (R&D) collaboration in the form of a scientific partnership focused on complementary research projects which could develop advanced, future-proof technologies with direct applications in the field of dermatology. Today’s announcement

NEWS DESK

PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects

News Desk 2 25/07/2024

Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet.1The trials evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without topical calcineurin inhibitors (TCI), versus placebo in combination with TCS, with or

NEWS DESK

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

News Desk 2 19/06/2024

Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap. The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable

NEWS DESK

Galderma Launches Restylane® VOLYME™ in China

News Desk 2 24/05/2024

Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT™) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for

NEWS DESK

Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis

News Desk 2 07/05/2024

Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Singapore, Switzerland, and the United Kingdom, whose regulatory authorities are members of the Access Consortium. An approval decision is expected from

NEWS DESK

Galderma Delivers a Strong Start to the Year

News Desk 2 24/04/2024

Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. “We started the year strong, continuing on Galderma’s growth trajectory and celebrating our first days of trading on the SIX Swiss Exchange. This is a testament to our proven integrated dermatology strategy and the focus […]